LONDON, July 28, 2016 /PRNewswire/ -- Smith & Nephew
(NYSE:SNN; LSE:SN), the global medical technology business, today
announces the first surgical case of its robotics-assisted total
knee replacement procedure. The new approach, which recently
received 510(k) clearance from the US Food and Drug Administration,
uses the NAVIO Surgical System to implant the JOURNEY™ II BCS and
CR total knee systems.
The surgery was performed by Dr. Brian
McGinley at the John T.
Mather Memorial Hospital in Port
Jefferson, NY. Dr. McGinley commented: "The handheld
robotics-assisted NAVIO platform provided me a precise and
efficient placement of the JOURNEY II BCS. I was delighted to
see how seamlessly it integrated into our workflow."
During a total knee replacement surgery, the NAVIO system is
designed to deliver consistent and accurate results through the
utilization of a robotics-assisted hand piece, navigation and NAVIO
specific cut guides, all of which enable better patient outcomes.
The NAVIO intra-operative planning software uses 3D surface capture
to predict joint laxity, enable precise implant positioning, and
customize a solution for each patient. Unlike other
robotics-assisted platforms, the NAVIO system does not require a
pre-operative CT scan.
While Smith & Nephew's JOURNEY PFJ, JOURNEY UNI, STRIDE™ and
ZUK partial knee systems have been widely available for use with
the NAVIO system, this milestone marks the first time orthopaedic
surgeons will have access to the robotics-assisted technology when
implanting the company's total knee systems. Currently available
for the JOURNEY II total knee system, additional total knee systems
are expected to be supported by the NAVIO system in future
releases.
"We're excited to introduce the combination of our NAVIO
Surgical System and the JOURNEY II total knee system to the
orthopaedic community," said Mike
Donoghue, Senior Vice President of Global Marketing for
Orthopaedics at Smith & Nephew. "Surgeons now have access to a
highly portable, robotics-assisted technique that marks the next
step in Smith & Nephew's pioneering approach to joint
reconstruction. This cost-effective procedure positions us
particularly well in the US market, where bundled payments and
ambulatory surgery centers have shifted focus to the economic
feasibility and overall value of new technology for joint
replacement procedures."
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2015 were more
than $4.6 billion. Smith & Nephew
is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document
may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain
marks registered US Patent and Trademark Office.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/smith--nephews-navio-surgical-system-achieves-robotics-assisted-milestone-for-total-knee-replacement-surgery-300305347.html
SOURCE Smith & Nephew